The proof behind the system is in the real-world evidence
Top healthcare companies trust us to help thousands of patients manage their medication schedule day after day.
Top healthcare companies trust us to help thousands of patients manage their medication schedule day after day.
A proven behavioral change system
Aidia is a proven behavioral change system that integrates effortlessly into a patient’s life and works in real-time to focus care team interventions when they can make a difference.
Given the high level of investment to bring a medicine to market and then to ensure a patient is able to benefit from it, it’s critical that a patient has a positive medication onboarding experience. Aidia has consistently proven the ability, across disease states, to help patients start and stay on their medicine.
Patients benefit from additional prescriptions
In addition to significantly improving onboarding and retention Aidia has proven to improve patient compliance with their dosing schedule resulting in less medication gap days. This combination of increased retention and compliance with dosing schedule ensures the patient is able to benefit from additional prescriptions.
Significantly improved retention regardless of payer
Regardless of payer, the AdhereTech cohort 12-month retention significantly outperforms that of the non-AdhereTech control group.
Consistently proven results across different therapies and disease states, published by top pharmacies and academic health centers.
Avella Pharmacy
UnitedHealth Group
26% increased time on therapy
per patient, per year
Journal of Managed Care & Specialty Pharmacy (JMCP)
Avella Specialty Pharmacy, UnitedHealth Group
4.7 out of 5
overall patient satisfaction
Journal of Acquired Immune Deficiency Syndromes (JAIDS)
Weill Cornell Clinical Trials Unit
+1 additional dose,
per week, per levels in the blood
Avella Pharmacy
UnitedHealth Group
Analysis of patients using the Aidia System across five specialty medications showed consistent improvements in adherence, duration, refills, and patient experience compared with control groups not using the system:
15% increased adherence
at the dose-level
9% increase in fill rates
per patient, per year
1-2 additional fills
of medication per patient per year
“AdhereTech improves adherence and generates 1-2 additional fills of medication per patient per year, across multiple specialty medications and diseases.”
“Patient feedback is overwhelmingly positive, with the average patient satisfaction rating at 4.7 out of 5.”
“AdhereTech program continues to achieve stellar results for patients. One of the many benefits is that the program delivers additional support to patients or caregivers when it’s needed most, leading to a great patient experience.”
Journal of Managed Care & Specialty Pharmacy (JMCP)
Avella Specialty Pharmacy, UnitedHealth Group
Peer-reviewed
In a real-world pharmacy setting, the Aidia System with pharmacist interventions was associated with increased medication adherence:
12.6% increased adherence
with more consistent dose-time behavior compared with control group
1 additional cycle
of medication taken compared with control group over 6 months
5 out of 5
(strongly agree) rating for ease of setup and ease of use
“[AdhereTech] demonstrated a significantly higher median adherence of 100% compared with the control arm median adherence of 87.4% (P=0.001).”
“[AdhereTech patients] had more regulated behavior and took a greater proportion of doses during the optimal 2-hour dosing window (83% vs 22%; P<0.001).”
“In addition to improved adherence, [AdhereTech patients] completed more cycles.”
Journal of Acquired Immune Deficiency Syndromes (JAIDS)
Weill Cornell Clinical Trials Unit
Peer-reviewed
Key study shows adherence intervention in patients with HIV, using the Aidia System, resulted in fewer missed doses of medication.
1 additional dose per week
compared with control group
Patients using AdhereTech had optimal levels of medication in the blood “on the order of around one additional dose per week” vs patients not using AdhereTech.
“Using an objective novel marker, intracellular tenofovir diphosphate by dried blood spot, demonstrates the best evidence of the use of [AdhereTech] to improve adherence.”
Conducted and published by Dr. Roy Gulick, Chief of the Division of Infectious Diseases, Former Chairman of the FDA Antiviral Drugs Advisory Committee
Partner with us
Speak with a representative about how to support your organization’s patient populations.
Contact Us